Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: A cost-utility analysis in a country with an existing school-girl program

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Pearson, Amber L ^a   Kvizhinadze, Giorgi ^a   Wilson, Nick ^a   Smith, Megan ^b   Canfell, Karen ^b   Blakely, Tony ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; BOY; CANCER INCIDENCE; CANCER SURVIVAL; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; MORTALITY; NEW ZEALAND; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; NEW ZEALAND; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SCHOOL HEALTH SERVICES; SCHOOLS; VACCINATION;

EID: 84902947387     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-351     Document Type: Article

References (41)

1. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against Human Papillomavirus-related disease in developed countries. Vaccine 2012, 30S(5):f157-f167.
2. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya O, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Chymura MJ, Anderson RN, Yankey BK Edwards D. Annual report of the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013, 105(3):175-201.
3. Hocking J, Stein A, Conway E, Regan DG, Grulick A, Law M, Brotherton J. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer 2011, 104(5):886-891.
4. Jin F, Stein A, Conway E, Regan DG, Law M, Brotherton J, Hocking J, Grulich AE. Trends in anal cancer in Australia, 1982-2005. Vaccine 2011, 29(1):2322-2327.
5. Elwood JM, Youlden DR, Chelimo C, Ioannides SJ, Baade PD. Comparison of oropharyngeal and oral cavity squamous cell cancer incidence and trends in New Zealand and Queensland, Australia. Cancer Epidemiol 2014, in press.
6. Hammad A, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into naitonal human papillomavirus vaccination programme: national surveillance data. BMJ 2013, 346:f2032.
7. Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparen P, Simard JF. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012, 206(6):860-866.
8. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J 2011, 124(1339):51-58.
9. ESR Sexually transmitted infectious diseases in New Zealand 2011 2012, Porirua: ESR, http://www.surv.esr.cri.nz/PDF_surveillance/STISurvRpt/2011/2011AnnualSTIRpt.pdf; 2012, ESR.
10. MMWR Recommendations of the use of quadrivalent human papillomavirus vaccine in laes - Advisory committee on immunization practices (ACIP), 2011. Morb Mortal Wkly Rep 2011, 60(50):1705-1708. MMWR.
11. Australian Government Department of Health and Ageing Immunise Australia Program. The National HPV Vaccination Program Register 2011, http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv. 2011, Australian Government Department of Health and Ageing.
12. Massey PD, Durrheim DN. Universal human papillomavirus vaccination of Australian boys - neither cost-effective nor equitable. Med J Aust 2012, 196(7):446.
13. Brisson M, van de Velde N, Franco E, Drolet M, Boily M. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011, 204:372-376.
14. French K, Barnabas R, Lehtinen M, Kontula O, Pukkala E, Dillner J, Garnett G. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex- specific pattern of vaccination in Finland. Br J Cancer 2007, 96(3):514-518.
15. Smith M, Lew J, Walker R, Brotherton J, Nickson C, Canfell K. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 2011, 29(48):9112-9122.
16. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectivenss of male HPV vaccination in the United States. Vaccine 2011, 29:8443-8450.
17. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010, 10(12):845-852.
18. Cummings T, Zimet G, Brown D, Tu W, Yang Z, Fortenberry J, Shew M. Reuction of HPV infections through vaccination among at-risk urban adolescents. Vaccine 2012, 30(37):5496-5499.
19. Blakely T, Foster R, Wilson N. BODE3 Team: Burden of Disease Epidemiology, Equity and Cost-Effectiveness (BODE3) Study Protocol. Version 2.0. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - Technical Report NoXXX. Wellington 2012, Wellington: Department of Public Health, University of Otago.
20. Blakely T, Kvizhinadze G, Karvonen T, Pearson AL, Smith M, Wilson N. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine 2014, [Epublication date 21 March 2014]: doi:10.1016/j.vaccine.2014.02.071.
21. Prices and purchasing power parities (PPP) [http://www.oecd.org/std/prices-ppp/].
22. Kvizhinadze G, Blakely T. Projected New Zealand Lifetables. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme (BODE3) Technical Report: Number 4 2011, Wellington: Department of Public Health, University of Otago.
23. Blakely T, Costilla R, Soeberg M. Cancer excess mortality rates over 2006-2026 for ABC-CBA. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - Technical Report No10 2012, Wellington: Department of Public Health, University of Otago, Wellington.
24. Costilla R, Atkinson J, Blakely T. Incorporating Ethnic and Deprivation Variation to Cancer Incidence Estimates over 2006-2026 for ABC-CBA. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme - Technical Report No5 2011, Wellington: Department of Public Health, University of Otago, Wellington.
25. Ministry of Health New Zealand Cancer Registry 2013, Wellington: Ministry of Health, Ministry of Health.
26. Smith M, Walker R, Canfell K. National Cervical Screening Programme Monitoring Report Number 34: 1 July - 31 December 2010 2012, Wellington: National Screening Unit, Ministry of Health.
27. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR, Moncada G, Dutta A, Sazawal S, Dyer A, Seiler J, Aboyans V, Baker L, Baxter A, Benjamin EJ, Bhalla K, Bin Abdulhak A, Blyth F, Bourne R, Braithwaite T, Brooks P, Brugha TS, Bryan-Hancock C, Buchbinder R, Burney P, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2129-2143.
28. Ministry of Health HPV immunisation programme 2013, Wellington: Ministry of Health, Ministry of Health.
29. Liddon N, Hood J, Wynn BA, Markowitz LE. Acceptibility of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health 2010, 46(2):113-123.
30. Ramrakha S, Bell M, Paul C, Dickson N, Moffitt T, Caspi A. Childhood Behavior Problems Linked to Sexual Risk Taking in Young Adulthood: A Birth Cohort Study. J Am Acad Child Adolesc Psychiatry 2007, 46(10):1272-1279.
31. Boyce W. Sexual Health of Canadian Youth: Findings from the Canadian Youth Sexual Health and HIV/AIDS Study. Can J Hum Sex 2006, 15(2):59.
32. Marra F, Ogilvie G, Colley L, Kiliewer E, Marra C. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009, 4(85):111-115.
33. The Institute of Environmental Science and Research Ltd Sexually Transmitted Infections in New Zealand: Annual Surveillance Repor 2011, Porirua, New Zealand: ESR, The Institute of Environmental Science and Research Ltd.
34. WHO Choosing interventions that are cost effective (WHOCHOICE). vol. Table: Threshold values for intervention costeffectiveness by region 2012, Geneva: World Health Organization, WHO.
35. Chesson H, Ekwueme D, Saraiya M, Dunne E, Markowitz L. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29(46):8443-8450.
36. Elbasha E, Dasbach E. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28(42):6858-6867.
37. Kim J, Goldie S. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009, 339:b3884.
38. Malagon T, Joumier V, Boily M, Van de Velde N, Drolet M, Brisson M. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis. Vaccine 2013, 31:1740-1747.
39. Litmus HPV Immunisation Programme Implementaiton Evaluation: File Report 2012, Wellington: Prepared for the New Zealand Ministry of Health, vol. 1, Litmus.
40. Hariri S, Markowitz LE, Dunne EF, Unger ER. Population Impact of HPV Vaccines: Summary of Early Evidence. J Adolesc Health 2013, 53(6):679-682.
41. Malagón T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(10):781-789.